Title : Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients.

Pub. Date : 2020 Jan-Apr

PMID : 32232055






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan arginine vasopressin Homo sapiens